Dow Corning’s newest liquid silicone rubbers (LSR) for the medical device industry promise improved molding and mechanical properties.

Click Image to Enlarge

Dow Corning expanded its Silastic and CS Series LSRs with six new grades targeting healthcare applications.

Dow Corning, Midland, Mich., dowcorning.com, introduced the new Silastic Q7-78XX series of elastomers, comprised of three new LSRs with Shore A hardnesses of 40, 50 and 70, at MD&M West (Feb. 9-11, Anaheim, Calif.). In addition, the company expanded the Dow Corning Series LSRs for short term or non-implant applications, with three additional products.

 

The additions to the Silastic line—Q7-7840, Q7-7850, Q7-7870—reportedly offer improved molding performance with a formulation created to reduce mold fouling. In addition to enhanced throughput and limited cleaning and change-outs over time, the materials feature improved mechanical properties, including greater tear strength and compression set. As with all nine Silastic grades, which are two-part platinum-catalyzed LSRs, the newest are approved for implants of up to 90 days.

 

The additions to the Dow Corning C6 Series LSRs—C6-740, C6-750, C6-770—also reportedly offer improved molding performance, reduced mold fouling, and greater mechanical properties. In addition, Dow Corning said there is no need to post cure parts to stabilize physical properties, adding that the two-part platinum-catalyzed LSRs are manufactured in a dedicated healthcare facility.

 

Dow Corning said the silicone elastomers share a uniform chemistry for highly reproducible processing and performance across medical device designs. The company also noted that it manufactures these new silicones, and its full elastomers portfolio, under strict change and process control systems to help ensure high quality and consistency, key to all markets but of particular interest in medical.